Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Natpara (parathyroid hormone) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Patients with Chronic Hypoparathyroidism Refractory to Standard Therapy: Continuous subcutaneous PTH infusion resulted in rapid clinical and biochemical improvement without severe adverse events.
• Comparative Effectiveness of PTH Replacement vs. Standard Therapy: PTH replacement therapy showed no significant difference in serum calcium levels compared to standard calcium and vitamin D therapy, with a trend towards lower 24-hour urinary calcium in the PTH group, though this was not statistically significant.
• Management of Postoperative Hypoparathyroidism: Different early postoperative hypoparathyroidism treatment strategies were effective in preventing major hypocalcemia-related complications, with no significant difference in long-term hypoparathyroidism incidence among various supplementation protocols.
• The incidence of serious adverse events was similar between PTH replacement therapy and control groups (RR 1.35; 95% CI 0.58, 3.16; P = 0.49).
• There is no population types or subgroups information available in the reviewed studies.